Biofrontera Prepares Market Launch in Belgium for Its Non-Melanoma Skin Cancer Drug Ameluz(R)

Strategic Insights -

Biofrontera AG, a biopharmaceutical company focusing on skin cancer, has completed nearly all preparations for the launch of its non-melanoma skin cancer drug Ameluz(R) in Belgium. The company anticipates first sales in the first quarter of 2015 and has secured pricing for the Belgian market. The therapy will be fully reimbursed by the Belgian healthcare system, providing a significant advantage for patients. The distribution of Ameluz(R) in Belgium will be handled by Bipharma N.V., a company that has already successfully distributed the product in the Netherlands.

Key Takeaways:

  • Biofrontera AG has completed nearly all preparations for the market launch of Ameluz(R) in Belgium, with first sales expected in Q1 2015.
  • The therapy will be fully reimbursed by the Belgian healthcare system, providing a significant advantage for patients.
  • Pricing has been agreed for the Belgian market, and distribution will be handled by Bipharma N.V.
  • Ameluz(R) has received recognition for its high efficacy and economic viability in treating actinic keratosis in comparison to competing products.
  • Biofrontera AG expects to launch Ameluz(R) in further markets in Europe this year, with a focus on the approval of basal cell carcinoma.
  • The company has made significant progress in recruiting patients for the Phase III study for basal cell carcinoma, with over two-thirds of the required 360 patients already recruited.

Statistics:

  • Q1 2015: expected first sales of Ameluz(R) in Belgium (Source: Biofrontera AG)
  • Over two-thirds of the required 360 patients have been recruited for the Phase III study for basal cell carcinoma (Source: Biofrontera AG)
  • Belgium's healthcare system will fully reimburse Biofrontera's non-melanoma skin cancer drug Ameluz(R) (Source: Biofrontera AG)
  • Bipharma N.V. will distribute Ameluz(R) in Belgium (Source: Biofrontera AG)
  • Over 200,000 cases of actinic keratosis are reported annually in the European Union (Source: European Association of Dermato-Cosmetology)
  • Ameluz(R) has been approved in Europe for the treatment of mild and moderate actinic keratosis (Source: European Medicines Agency)

Sources:

  • Biofrontera AG (26 January 2015) - "Biofrontera prepares market launch in Belgium for its non-melanoma skin cancer drug Ameluz(R)"
  • Globenewswire (26 January 2015) - "Biofrontera AG: Biofrontera prepares market launch in Belgium for its non-melanoma skin cancer drug Ameluz(R)"
  • European Association of Dermato-Cosmetology (n.d.) - "Actinic Keratosis"
  • European Medicines Agency (n.d.) - "Ameluz(R)"